Clinical trials: Neurological Disease
Migraine, Head Pain
A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache
The purpose of this study is to evaluate the effectiveness and safety of tramadol HCl/acetaminophen as a pain medication compared with placebo in the treatment of acute pain from a migraine headache.
- Conditions
- Migraine, Head Pain, Headache
- Trial name
- NCT00297375
- Testing
- tramadol HCl/acetaminophen
- Volunteers
- 375 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Migraine or Episodic Migraine
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
To evaluate the effect of AMG 301 compared to placebo on the change from the baseline period in monthly migraine days in subjects with migraine.
- Trial name
- NCT03238781
- Testing
- AMG 301
- Where
- 49 sites in United States, Austria and 6 more
- Volunteers
- 343 people
- Sponsor
- Amgen
Parkinson Disease
Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease
This clinical trial focus on the delivery of Cerezyme® in Parkinson's Disease (PD) patients using MR-guided focused ultrasound (MRgFUS) induced opening of the blood-brain barrier (BBB).
- Trial name
- NCT04370665
- Testing
- Exablate BBBD with Cerezyme
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- InSightec
Epilepsy
Comparison Of NeuroNaute Smart System to a Standard EleCTroencephalogram System in Hospital
The proposed study is designed to evaluate the performance of the Neuronaute in comparison with the gold standard EEG in patients with a regular appointment at the hospital.
- Trial name
- CONNECT (NCT03379272)
- Testing
- GOLDSTANDARD, NEURONAUTE
- Sponsor
- BioSerenity
Acute Pain
Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction
This study evaluated a new drug fixed-dose combination tablet (FDC) called tramadol/diclofenac at two different strengths (fixed doses of 25 milligrams [mg] of tramadol and of diclofenac or of 50 mg each).
- Trial name
- NCT03714672
- Testing
- Tramadol/Diclofenac 50/50, Tramadol/Diclofenac 25/25, Tramadol 50
- Where
- 8 sites in Mexico
- Volunteers
- 1,151 people
- Sponsor
- Grünenthal GmbH
Partial-onset Seizures
A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures
- Trial name
- NCT01618695
- Testing
- Perampanel
- Where
- 117 sites in Australia, China and 5 more
- Volunteers
- 940 people
- Sponsor
- Eisai Co., Ltd.
Parkinson's Disease
A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.
The purpose of this study is to assess the safety and tolerability of a dose of 95μg sNN0031 after intracerebroventricular administration to patients with Parkinson's disease
- Trial name
- NCT01829867
- Testing
- sNN0031
- Where
- 2 sites in Sweden
- Volunteers
- 5 people
- Sponsor
- Newron Sweden AB
Parkinson's Disease
A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease
The purpose of this clinical trial is to compare the safety and tolerability of two dose regimens of fipamezole in adult patients with Parkinson's Disease who are receiving levodopa.
- Trial name
- Fipamezole (NCT01149811)
- Testing
- Fipamezole ODT, Fipamezole ODT Cohort 2
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Bausch Health Americas, Inc.
Pain
Ibuprofen Versus Ibuprofen Plus Caffeine in the Treatment of Migraine.
Primary Objective: To compare the treatment groups in the reduction of pain score by at least 30 mm on a visual pain scale (VAS) at 60 minutes after study medication intake, compared to the baseline score (obtained before the…
- Trial name
- NCT01426971
- Testing
- IBUPROFEN + CAFFEINE, IBUPROFEN
- Sponsor
- Sanofi
Tinnitus, Hearing Loss, Cochlear Implant Users
Sound Therapy for Tinnitus Relief in Cochlear Implant Users
The aim of this exploratory study is to evaluate the use and effectiveness of sound therapy for tinnitus relief in cochlear implant users with tinnitus.
- Trial name
- NCT03026829
- Testing
- CART sound therapy
- Where
- 2 sites in Netherlands
- Volunteers
- 32 people
- Sponsor
- Cochlear
Acute Coronary Syndromes
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status…
- Trial name
- NCT01611272
- Where
- 23 sites in South Korea
- Volunteers
- 3,402 people
- Sponsor
- AstraZeneca
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
Multiple Sclerosis
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
The purpose of this study is to obtain long-term clinical data from patients approximately 15 years after their first clinical event, who participated in the former BENEFIT 304747 study and were treated at least once within that…
- Trial name
- NCT03269175
- Testing
- Brain MRI, Blood sampling
- Where
- 61 sites in Austria, Belgium and 16 more
- Volunteers
- 261 people
- Sponsor
- Bayer
Migraine
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.
- Trial name
- DRAGON (NCT03867201)
- Testing
- Erenumab
- Where
- 63 sites in China, India and 7 more
- Volunteers
- 557 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Korean Regulatory Post Marketing Surveillance for Somavert
Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)
- Trial name
- NCT05131100
- Testing
- Somavert
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- Pfizer
Migraine
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
- Trial name
- NCT05550207
- Testing
- AXS-07 (meloxicam-rizatriptan)
- Where
- 31 sites in United States
- Volunteers
- 100 people
- Sponsor
- Axsome Therapeutics, Inc.
Dermatomyositis
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.
- Trial name
- NCT05192200
- Testing
- Anti-Beta Interferon (PF-06823859)
- Where
- 25 sites in United States, Hungary and 2 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Hallux Valgus
Efficacy and Safety of Intranasal Morphine for Pain After Bunion Surgery
Study designed to evaluate the efficacy and safety of Intranasal (IN) Morphine Nasal Spray (MNS075) 3.75 mg, 7.5 mg, 15 mg, and 30 mg, intravenous (IV) morphine 7.5 mg, or IN placebo in patients with moderate to severe…
- Trial name
- NCT00388011
- Testing
- Intranasal Morphine (MNS075) 3.75 mg, Intravenous Morphine 7.5 mg, Intranasal morphine (MNS075) 7.5 mg
- Volunteers
- 187 people
- Sponsor
- Javelin Pharmaceuticals
Chronic Low-back Pain, Disc Degeneration
Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain
The purpose of this clinical study is to evaluate the safety, tolerability, and efficacy of CordSTEM-DD, an allogeneic umbilical cord-derived mesenchymal stem cell, as a cell-therapeutic drug in patients with chronic low back…
- Trial name
- NCT04530071
- Testing
- CordSTEM-DD (0.7 x 10^7 cells), CordSTEM-DD (2.1 x 10^7 cells)
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- CHABiotech CO., Ltd
Highly Drug-resistant Focal Epilepsy
A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
This study is to assess the efficacy, safety, and tolerability of the investigational drug UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in Europe.
- Trial name
- NCT02495844
- Testing
- UCB0942
- Where
- 18 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 55 people
- Sponsor
- UCB Biopharma S.P.R.L.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.